



ALTERNATIVE TO PTO/SB/08A/B (09/06)

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/592,918
				Filing Date	September 15, 2006
				First Named Inventor	Toshihiro Nakajima
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	2	Attorney Docket Number	L7350.0011

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	†
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)					
/DS/	BA	WO-02/052007		07-04-2002	Locomogene, Inc.		
	BB	JP-2003-89647-A		03-28-2003	Takada Seiyaku Kabushiki Kaisha		
	BC	WO-2003/018033-A1		03-06-2003	The University of British Columbia		
	BD	JP-2002-10784-A		01-15-2002	Teijin Ltd.		
	BE	JP-2003-525243-A		08-26-2003	The University of British Columbia		
	BF	JP-7-324035-A		12-12-1995	LTT Institute Co., Ltd.		
	BG	JP-7-145062-A		06-06-1995	LTT Institute Co., Ltd.		
	BH	WO-01/76630-A1		10-18-2001	Kyowa Hakko Kogyo Kk et al.		
	BI	WO-01/21793-A1		03-29-2001	Miyasaka Nobuyuki et al.		
	BJ	WO-00/53194-A1		09-14-2000	Takata Seiyaku Co Ltd et al.		
	BK	JP-2001-503785-A		03-21-2004	Angiotech Pharmaceuticals, Inc.		
	BL	WO-00/38693-A1		07-06-2000	Toray Industries et al.		
	BM	WO-01/51480-A1		07-19-2001	Takara Shuzo Co et al.		
	BN	WO-01/95921-A1		12-20-2001	Gifu Shellac Mfg Co Ltd et al.		
	BO	WO-97/47622-A1		12-18-1997	Japan Tobacco Inc et al.		
	BP	JP-8-73453-A		03-19-1996	Otsuka Pharmaceutical Co., Ltd.		
	BQ	WO-99/28457-A1		06-10-1999	Otsuka Pharma Co Ltd et al.		
/DS/	BR	WO-2005/018675-A1		03-03-2005	Locomogene, Inc.		

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Dana Shin/	Date Considered	01/15/2008
--------------------	-------------	-----------------	------------



ALTERNATIVE TO PTO/SB/08A/B (09/06)

<b>Substitute for form 1449/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/592,918
				Filing Date	September 15, 2006
				First Named Inventor	Toshihiro Nakajima
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	L7350.0011

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials <sup>*</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
/DS/	CA	Cattaneo, M., et al.; Identification of a region within SEL1L protein required for tumour growth inhibition. Gene, 2004, 326, pages 149 to 156 (Disclosed are that tumour growth is inhibited by SEL1L having Hrd3 motif and that inhibiting action of tumour cell growth is weakened by deletion mutant of SEL1L)		
/DS/	CB	Amano, T., et al., Synoviolin/Hrd1, an E3 ubiquitin ligase, as a novel pathogenic factor for arthropathy., Genes & Development, 2003, 17, pgs. 2436 to 2449.		
/DS/	CC	Gardener, R.G., et al., Endoplasmic Reticulum Degradation Requires Lumen to Cytosol Signaling: Transmembrane Control of Hrd1p by Hrd3p., Journal of Cell Biology, 2000, 151(1), pgs. 69 to 82.		
/DS/	CD	Naoko Yagishita, et al., "Kansetsu Rheumatism Hassho no Byoin Bunshi Synoviolin", Igaku no Ayumi, 02 October 2004, 211(1), pgs. 124 to 128.		
/DS/	CE	Yagishita, N., et al., Essential Role of Synoviolin in Embryogenesis., Journal of Biological Chemistry, 2005, 280, pgs. 7909 to 7916.		

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Dana Shin/	Date Considered	01/15/2008
-----------------------	-------------	--------------------	------------